Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • October 2010 (Revised November 2010)
  • Background Note
  • HBS Case Collection

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
  • Format:Print
  • | Pages:14
ShareBar

Abstract

PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even death if they took PIavix. As a result, the FDA had added a black box warning—the agency's most severe—to Plavix's label in 2010. In addition, it had been discovered that the common combination of Plavix and Prilosec, an over-the-counter drug, could adversely affect patients. Finally, Plavix faced new competition from two new drugs with different mechanisms of action. This case reviews the recent history of Plavix in greater detail to encourage a discussion of the following questions: How might the current manufacturers of Plavix handle these emerging threats to their leading blockbuster? How might Plavix's potential competitors utilize Plavix's mixed history to their advantage? How should genotyping be integrated into the clinical care of patients in the light of emerging knowledge?

Keywords

Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry

Citation

Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
  • Educators
  • Purchase

About The Author

Richard G. Hamermesh

→More Publications

More from the Authors

    • January 17, 2022
    • Harvard Business Review (website)

    Reducing Racial Disparities in Cancer Outcomes

    By: Kathy Giusti and Richard G. Hamermesh
    • June 11, 2021
    • Harvard Business Review Digital Articles

    Addressing Demographic Disparities in Clinical Trials

    By: Kathy Giusti, Richard G. Hamermesh and Mark Krasnow
    • September 30, 2020
    • Harvard Business Review Digital Articles

    How Nonprofit Foundations Can Sustainably Fund Disease Research

    By: Richard G. Hamermesh and Kathy Giusti
More from the Authors
  • Reducing Racial Disparities in Cancer Outcomes By: Kathy Giusti and Richard G. Hamermesh
  • Addressing Demographic Disparities in Clinical Trials By: Kathy Giusti, Richard G. Hamermesh and Mark Krasnow
  • How Nonprofit Foundations Can Sustainably Fund Disease Research By: Richard G. Hamermesh and Kathy Giusti
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College